ECONOMIC IMPACT OF RENAL REPLACEMENT THERAPY MODALITY SELECTION ON CHRONIC DIALYSIS PROGRESSION IN HOSPITALIZED PATIENTS

Author(s)

Lucas Grozewicz Scultori, Pharmacist1, CRISTINA N. FERREIRA, Sr., MBA, MSc, PharmD1, LAIS MARQUES PIMENTA, Pharmacist2, DOUGLAS GEMENTE, Physician3.
1Laboratórios B.Braun, Rio de Janeiro, Brazil, 2Universidade Federal Fluminense, Rio de Janeiro, Brazil, 3Hospital Santa Marcelina, São Paulo, Brazil.
OBJECTIVES: To evaluate the long-term financial consequences and economic impact of renal replacement therapy modality selection—specifically Continuous Kidney Replacement Therapy (CKRT) versus Sustained Low-Efficiency Dialysis (SLED)—on chronic dialysis progression in hospitalized patients with acute kidney injury (AKI).
METHODS: An economic evaluation was conducted from a private payer perspective over a 5-year treatment horizon. Utilizing published clinical data, a 5% AKI incidence rate was applied to a hypothetical cohort of 1,000 hospitalized patients (50 AKI cases). The projection of patients progressing to chronic dialysis was based on clinical evidence showing post-discharge dependence rates of 23% for SLED and 6% for CKRT. A financial model calculated the 5-year cumulative costs using an annual chronic dialysis baseline of BRL 39,840.15 per patient.
RESULTS: In the cohort of 50 AKI patients, SLED modality resulted in 12 individuals evolving to chronic dialysis, generating a 5-year cumulative cost of BRL 2,290,808.63. Conversely, selecting CKRT restricted progression to only 3 patients, totaling BRL 597,602.25. Opting for CKRT over SLED demonstrated an economic impact resulting in up to a 74% cost reduction for chronic dialysis management.
CONCLUSIONS: Initial modality selection during acute hospitalization acts as a critical economic driver for long-term healthcare spending. Choosing CKRT significantly reduces progression to chronic dialysis and mitigates substantial expenditures, optimizationing medical resources and health system sustainability

Conference/Value in Health Info

2026-11, ISPOR Europe 2026, Vienna, Austria

Value in Health, Volume 29, Issue 12S

Code

MT26

Topic

Clinical Outcomes, Economic Evaluation, Medical Technologies

Disease

Urinary/Kidney Disorders

Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×